Showing 1011-1020 of 19239 results for "".
Advancing Care in Locally Advanced HNSCC: Integrating Perioperative Immunotherapy and Multimodal Strategies
https://reachmd.com/programs/cme/advancing-care-in-locally-advanced-hnscc-integrating-perioperative-immunotherapy-and-multimodal-strategies/35704/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO Study
https://reachmd.com/clinical-practice/psychiatry-and-mental-health/valbenazine-and-patient-centered-outcomes-in-td-insights-from-the-kinect-pro-study/36175/Valbenazine and Patient-Centered Outcomes in TD: Insights From the KINECT-PRO StudyOngoing Clinical Trials in AML With Menin Inhibitors
https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
https://reachmd.com/programs/project-oncology/evaluating-alemtuzumab-in-adult-all-insights-from-a-phase-12-clinical-trial/32993/Alemtuzumab may have potential as an adult acute lymphoblastic leukemia treatment. Dive deeper into its safety, efficacy, and implications for care.No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
https://reachmd.com/programs/acc-action-center/no-improvements-in-cv-outcomes-at-90-days-with-human-apoa-1-infusions-post-mi/24288/ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
https://reachmd.com/programs/cme/beyond-the-horizon-in-multiple-myeloma-harnessing-novel-celmod-mechanisms-for-increased-antimyeloma-activity/35916/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityEvaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.